PhRMA Funnels Millions to Groups Fighting Drug Pricing Reforms
The pharma lobby gave more than $16 million in 2022 to advocacy groups, many of them ostensibly “grassroots,” that are battling the Medicare drug price negotiations now underway.
The pharma lobby gave more than $16 million in 2022 to advocacy groups, many of them ostensibly “grassroots,” that are battling the Medicare drug price negotiations now underway.
The maker of Ozempic and Wegovy has recently hired a dozen new lobbyists to work on the issue of obesity and medication coverage.
The bundle was given as the health insurance industry was lobbying against Medicare dental, vision, and hearing coverage being included in the Build Back Better Act.
Rep. Josh Gottheimer (D-N.J.) is the unofficial leader of a bloc of conservative Democrats opposing the up to $3.5 trillion budget reconciliation package.